The Journal of Thoracic and Cardiovascular Surgery
Volume 117, Issue 4 , Pages 744-750 , April 1999

The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer

Received 17 June 1998 ,Revised 21 September 1998 ,Accepted 19 October 1998.

References 

  1. Shepherd FA. Future directions in the treatment of lung cancer. Semin Oncol. 1994;21:48S–62S
  2. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  3. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, et al.  Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998;16:622–634
  4. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia Group B trial (CALGB) 8433 Trial. J Natl Cancer Inst. 1996;88:1210–1215
  5. Rosell R, Font A, Pifarre A, Canela M, Maurel J, Arellano A. The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest. 1996;109:102S–106S
  6. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992;52:4799–4804
  7. Gazdar AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer. 1992;69:1592–1599
  8. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442–1455
  9. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967
  10. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847–852
  11. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al.  Aberrant p53 expression predicts clinical resistance to cisplatinum-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995;55:5038–5042
  12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  13. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc. 1972;135:185–207
  14. Lehmann TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, et al.  p53 mutations, ras mutation, and p53–heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991;51:4090–4096
  15. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee LS, et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  16. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R, et al.  Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemotherapy: a Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993;105:97–106
  17. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855–4878
  19. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3–15
  20. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer. 1994;69:26–31
  21. Wynford-Thomas D. p53 in tumor pathology: can we trust immunohistochemistry?. J Pathol. 1992;166:329–330
  22. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996;88:173–182
  23. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998;16:1207–1217

☆ Supported by the Österreichische Nationalbank, project number 7003.

☆☆ Address for reprints: Daniela Kandioler-Eckersberger, MD, Department of Surgery, University of Vienna-Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

★ 12/1/95291

PII: S0022-5223(99)70295-3

The Journal of Thoracic and Cardiovascular Surgery
Volume 117, Issue 4 , Pages 744-750 , April 1999

Article Tools

* Image Usage & Resolution